Computer-aided drug design in anti-cancer drug discovery: What have we learnt and what is the way forward? ?
Opeyemi Iwaloye,Paul Olamide Ottu,Femi Olawale,Olorunfemi Oyewole Babalola,Olusola Olalekan Elekofehinti,Babatomiwa Kikiowo,Abayomi Emmanuel Adegboyega,Henry Nnaemeka Ogbonna,Covenant Femi Adeboboye,Ibukun Mary Folorunso,Aderonke Elizabeth Fakayode,Moses Orimoloye Akinjiyan,Sunday Amos Onikanni,Sergey Shityakov,Iwaloye Opeyemi,Olamide Paul,Babalola Olorunfemi
DOI: https://doi.org/10.1016/j.imu.2023.101332
2023-08-19
Informatics in Medicine Unlocked
Abstract:The escalating prevalence of cancer on a global scale, coupled with the inadequacies of present-day therapies and the emergence of drug-resistant cancer strains, has necessitated the development of additional anti-cancer drugs. The traditional drug discovery process is long and complex, and the high failure rate of new drugs in clinical trials further highlights the need for computational approaches in anti-cancer drug discovery. Computer-aided drug design (CADD), including molecular docking, molecular dynamics simulations, QSAR analysis, and machine learning, are employed to forecast the efficacy of potential drug compounds and pinpoint the most auspicious compounds for subsequent testing and advancement. This article provides an overview of contemporary computational approaches employed in the design of anti-cancer drugs. It highlights a range of small molecules that have been identified as capable of impeding cancer growth and migration through various mechanisms, including cell cycle arrest/apoptosis, signal transduction inhibition, angiogenesis, epigenetics, and the hedgehog pathway. It also examines the constraints of computational techniques and presents remedies to surmount these limitations in the development and identification of efficacious anticancer compounds.